Cargando…
Development of pulmonary sarcoidosis in Crohn’s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review
BACKGROUND: Inflammatory bowel disease (IBD) is chronic inflammation of the gastrointestinal tract, although its etiology has largely been unclear. Tumor necrosis factor inhibitors (TNF-I) are effective for the treatment. Recently, biosimilars of TNF-I, such as CT-P13, have been developed and are th...
Autores principales: | Kashima, Shin, Moriichi, Kentaro, Ando, Katsuyoshi, Ueno, Nobuhiro, Tanabe, Hiroki, Yuzawa, Sayaka, Fujiya, Mikihiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513323/ https://www.ncbi.nlm.nih.gov/pubmed/34641810 http://dx.doi.org/10.1186/s12876-021-01948-6 |
Ejemplares similares
-
A case report of drug-induced liver injury due to the infliximab biosimilar
CT-P13 on switching from original infliximab in a patient with Crohn’s
disease
por: Kashima, Shin, et al.
Publicado: (2022) -
Infliximab Extends the Duration until the First Surgery in Patients with Crohn's Disease
por: Sakatani, Aki, et al.
Publicado: (2013) -
Long-term effectiveness and safety of infliximab-biosimilar: A multicenter Phoenix retrospective cohort study
por: Kazama, Tomoe, et al.
Publicado: (2023) -
Pilot study of endoscopic retrograde 3-dimensional – computed tomography enteroclysis for the assessment of Crohn’s disease
por: Tanabe, Hiroki, et al.
Publicado: (2017) -
Increased dosage of infliximab is a potential cause of Pneumocystis carinii pneumonia
por: Iwama, Takuya, et al.
Publicado: (2016)